Clinical Trial Update: Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 trial characterising 24-hour FEV1 time profiles for inhaled BI 1744 CL and inhaled Foradil in patients with chronic obstructive pulmonary disease; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1744 CL
• Foradil (formoterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-06-27